Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for prevention of postpartum depressive symptoms after cesarean section
IRCT20090801002266N21Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Maternal depression (PND) comparing Dexmedetomidine with Placebo (2 arms). Primary endpoint: Effect of dexmedetomidine on perinatal depression scores after childbirth. Started Sep 2025; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
Maternal depression (PND)
Beyond the preview
Go deeper on IRCT20090801002266N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N21.